Martin Salgueiro1, Michael Stribos2, Li Fang Zhang3, Mark Stevens1, Mohamed E Awad4, Mohammed Elsalanty4,5. 1. 1Oral and Maxillofacial Surgery Department, Dental College of Georgia, Augusta University, Augusta, GA USA. 2. 2Medical Student, Medical College of Georgia, Augusta University, Augusta, GA USA. 3. 3Department of Biostatistics and Epidemiology, Medical College of Georgia, Augusta University, Augusta, GA USA. 4. 4Department of Oral Biology and Diagnostic Sciences, Dental College of Georgia, Augusta University, Augusta, GA USA. 5. 5Department of Oral Biology, Dental College of Dentistry, Augusta University, 1120 15th Street, Room #2404E, Augusta, GA 30809 USA.
Abstract
OBJECTIVES: The low incidence yet severe presentation of medication-related osteonecrosis of the jaw (MRONJ) makes it necessary to develop reliable predictive and preventive strategies. This study explored the value of pre-operative carboxy-terminal collagen crosslinks (CTX) serum level in the prediction of osteonecrosis-related complications in patients on bisphosphonate therapy. PATIENTS AND METHODS: We examined patient records over 4 years (a total of 137 patients). Biometric data were extracted, in addition to type of treatment, CTX levels, drug holiday, procedure, complications, and co-morbidities. Non-parametric Wilcoxon two-sample tests were used to test the effect of initial CTX level in IV or PO and whether it was predictive of complications. Two independent proportion tests were used for testing the two different complication incident rates before or after the drug holiday. RESULTS: A total of 93 patients were included in the study, of whom 88.17% were female. A total of 11 patients were receiving IV bisphosphonates at the time of initial presentation, 82 oral bisphosphonates. Out of 64 patients who underwent invasive dental procedure (IDP) before a drug holiday, eight were on IV bisphosphonates. Three patients in this group experienced osteonecrosis-related complications (37.5%). Out of the remaining 56 patients on oral bisphosphonates, four (7.14%) developed complications, significantly lower than the IV bisphosphonate group (p = 0.0364). On the other hand, of the 34 patients placed on a drug holiday prior to IDP, only one subject developed complications related to osteonecrosis. Five subjects who had operations both before and after drug holiday did not experience any complications. No statistical difference was detected in complication rates based on initial CTX level (above versus below 150 pg/ml), gender, comorbidities, or total duration of bisphosphonate treatment (p = 0.2675). The sensitivity and specificity of CTX cutoff of 150 pg/ml in predicting osteonecrosis were 37.5% and 57.7, respectively. CONCLUSIONS: Serum levels of CTX by itself are not reliable as a predictive or preventive measure for such complications. Our data also suggested that a drug holiday of 5 months was not helpful in preventing osteonecrosis-related complications in patients on intravenous bisphosphonates. Further studies are urgently needed to develop adequate predictive and preventive strategies of MRONJ.
OBJECTIVES: The low incidence yet severe presentation of medication-related osteonecrosis of the jaw (MRONJ) makes it necessary to develop reliable predictive and preventive strategies. This study explored the value of pre-operative carboxy-terminal collagen crosslinks (CTX) serum level in the prediction of osteonecrosis-related complications in patients on bisphosphonate therapy. PATIENTS AND METHODS: We examined patient records over 4 years (a total of 137 patients). Biometric data were extracted, in addition to type of treatment, CTX levels, drug holiday, procedure, complications, and co-morbidities. Non-parametric Wilcoxon two-sample tests were used to test the effect of initial CTX level in IV or PO and whether it was predictive of complications. Two independent proportion tests were used for testing the two different complication incident rates before or after the drug holiday. RESULTS: A total of 93 patients were included in the study, of whom 88.17% were female. A total of 11 patients were receiving IV bisphosphonates at the time of initial presentation, 82 oral bisphosphonates. Out of 64 patients who underwent invasive dental procedure (IDP) before a drug holiday, eight were on IV bisphosphonates. Three patients in this group experienced osteonecrosis-related complications (37.5%). Out of the remaining 56 patients on oral bisphosphonates, four (7.14%) developed complications, significantly lower than the IV bisphosphonate group (p = 0.0364). On the other hand, of the 34 patients placed on a drug holiday prior to IDP, only one subject developed complications related to osteonecrosis. Five subjects who had operations both before and after drug holiday did not experience any complications. No statistical difference was detected in complication rates based on initial CTX level (above versus below 150 pg/ml), gender, comorbidities, or total duration of bisphosphonate treatment (p = 0.2675). The sensitivity and specificity of CTX cutoff of 150 pg/ml in predicting osteonecrosis were 37.5% and 57.7, respectively. CONCLUSIONS: Serum levels of CTX by itself are not reliable as a predictive or preventive measure for such complications. Our data also suggested that a drug holiday of 5 months was not helpful in preventing osteonecrosis-related complications in patients on intravenous bisphosphonates. Further studies are urgently needed to develop adequate predictive and preventive strategies of MRONJ.
Entities:
Keywords:
Bisphosphonates; Drug holiday; Osteonecrosis; Osteoporosis treatment; Prediction of complications
Authors: L S Rosen; D Gordon; M Kaminski; A Howell; A Belch; J Mackey; J Apffelstaedt; M Hussein; R E Coleman; D J Reitsma; J J Seaman; B L Chen; Y Ambros Journal: Cancer J Date: 2001 Sep-Oct Impact factor: 3.360
Authors: Regina Landesberg; Victoria Woo; Serge Cremers; Matthew Cozin; Darja Marolt; Gordana Vunjak-Novakovic; Stavroula Kousteni; Srikala Raghavan Journal: Ann N Y Acad Sci Date: 2011-02 Impact factor: 5.691
Authors: David K Lam; George K B Sándor; Howard I Holmes; A Wayne Evans; Cameron M L Clokie Journal: J Can Dent Assoc Date: 2007-06 Impact factor: 1.316
Authors: Keisuke Omori; Mitsunobu Otsuru; Kota Morishita; Saki Hayashida; Koki Suyama; Tomofumi Naruse; Sakiko Soutome; Masahiro Umeda Journal: Int J Environ Res Public Health Date: 2022-09-01 Impact factor: 4.614
Authors: Danila S de Alexandria Santos; Marco Vinícius de Sales Lima; Alexandre do Prado Scherma; Dárcio Kitakawa; Natália de Castro Magalhães; Felipe da Silva Peralta; Luis Felipe das Chagas E Silva de Carvalho Journal: Am J Case Rep Date: 2020-11-17
Authors: Lorenz Schubert; Guenter Russmueller; Heimo Lagler; Selma Tobudic; Elisabeth Heindel; Michael Kundi; Christoph Steininger Journal: Support Care Cancer Date: 2021-06-30 Impact factor: 3.603